← Back to Home

Using Light and Sound to Elicit Gamma Waves, Alzheimer’s Device Therapy Crosses an Early Clinical Threshold

A small, double-blind, sham-controlled trial showed that one hour a day of 40 Hz sensory stimulation had good safety and produced preliminary signals in daily function, cognition, and brain volume measures; it remains far from a clinical conclusion, but it moves a non-drug intervention into a more rigorous stage of validation.

By SURL BioNews

As Alzheimer’s disease treatment in recent years has largely centered on antibody drugs that clear amyloid protein, a device combining flashing-light glasses and sound headphones offers another possibility: instead of delivering drugs into the body, it stimulates brain networks at a fixed rhythm every day. Recent U.S. media reports on Cognito Therapeutics’ research progress have brought renewed discussion to this still-investigational therapy, called Spectris AD.

At the core of the technology is the use of 40 Hz light and sound to induce gamma waves in the brain. Gamma waves are associated with sensory processing, attention, and memory network activity; in patients with Alzheimer’s disease, these neural oscillations are often impaired. Cognito’s concept is to use visual and auditory pathways so that patients receive about one hour of stimulation daily at home, in an attempt to strengthen or synchronize neural networks that are gradually becoming disordered.

The main clinical basis for the same event comes from the OVERTURE trial, published in 2024 in Frontiers in Neurology. The study registration number was NCT03556280. It used a randomized, double-blind, sham-controlled design, lasted 6 months, and enrolled 76 patients aged 50 or older with mild to moderate Alzheimer’s disease and baseline MMSE scores between 14 and 26. Participants were assigned to the active treatment or sham treatment group in a 2:1 ratio, and used the device at home with caregiver assistance.

The strongest part of the results was safety and feasibility. The study report stated that overall adverse events were similar between the two groups, no amyloid-related imaging abnormalities were observed, and device-use adherence among completers was about 85% to 90%. This contrasts with some anti-amyloid antibody treatments: although the latter have become an important route in Alzheimer’s drug development, they require infusion and imaging monitoring, and also involve risk-management issues such as brain swelling or bleeding.

The efficacy signals must be interpreted more cautiously. OVERTURE was not statistically designed with confirmation of efficacy as its objective. The main composite scale, MADCOMS, as well as measures such as CDR-SB and ADAS-Cog14, did not clearly separate from the sham treatment group; however, ADCS-ADL, MMSE, and MRI whole-brain volume change showed nominally significant slowing. On its clinical research page, the company further presented the findings in percentages: compared with the control group, decline in daily function was reduced by 77%, MMSE cognitive decline by 76%, and MRI brain volume loss by 69%. These numbers have directional significance, but they still come from a small early-stage trial and are not equivalent to proof that the disease course can be modified.

Background Context

40 Hz sensory stimulation did not come out of nowhere. Early animal studies had shown that light and sound stimulation at specific frequencies might affect neural activity, amyloid, and tau-related pathology in Alzheimer’s disease models. However, whether mechanisms in animal brains can translate into perceptible clinical benefits in humans has always been one of the hardest gaps for neurotechnology to cross. WIRED’s report also mentioned that OVERTURE did not show a reduction in amyloid plaques on PET imaging, and the relevant biological mechanisms still require more refined research to clarify.

The next key step is a larger pivotal trial. Cognito said the HOPE study has completed enrollment of 673 participants at about 70 trial centers in the United States, and will evaluate the safety and effectiveness of Spectris AD in patients with mild to moderate Alzheimer’s disease. If the large trial can reproduce the signals in function, cognition, and brain atrophy, noninvasive neural stimulation may become an adjunctive or alternative path beyond drugs; if the results are inconsistent, OVERTURE will be viewed as an optimistic signal common in early exploration. For patients and caregivers, the real answer still has to come from larger, more diverse, and longer-duration clinical data.

References

  1. Men's Journal
  2. Frontiers in Neurology
  3. Cognito Therapeutics
  4. WIRED